idiopathic generalised epilepsy
Neurology · 2008–2021
4decisions
3medicines
2carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lacosamide Treatment of adults and children aged ≥4 years with idiopathic generalised epilepsy (IGE) with primary generalised tonic-clonic seizures (PGTCS) who have… | Mar 2021 | Recommended with restriction | input received |
| perampanel Treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 12 years or older. | Jul 2017 | Recommended with restriction | none received |
| perampanel Treatment of primary generalised tonic-clonic (PGTC) seizures in patients with idiopathic generalised epilepsy (IGE). | Jul 2016 | Not recommended | input received |
| levetiracetam Extension of PBS listing to include treatment of primary generalised tonic clonic seizures and generalised myoclonic seizures (juvenile myoclonic epilepsy) as… | Nov 2008 | Recommended with restriction | no section in document |
What the PBS pays
$47M in government benefit over 2024–25, across 929,330 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| levetiracetam | $23.1M |
| lacosamide | $15M |
| perampanel | $9.3M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.